经会阴前列腺穿刺活检的前列腺癌检出率:认知融合与软件融合的多中心分析
这项回顾性多中心研究比较了经会阴前列腺穿刺活检中认知融合与软件融合对临床显著前列腺癌的检出效果。共纳入490例患者(认知融合201例,软件融合289例),软件融合组系统性穿刺针数中位数多4针(95%CI 3-5)。调整分析显示两种融合方式检出临床显著前列腺癌的比值比为1.46(95%CI 0.82-2.58),差异无统计学显著。
要点
- 认知融合与软件融合经会阴穿刺检出临床显著前列腺癌相似,OR 1.46(95%CI 0.82-2.58)。
- 软件融合组系统性穿刺针数中位数较认知融合组多4针(95%CI 3-5)。
- 全部患者中临床显著前列腺癌检出率为44%。
核心结论
- 认知融合与软件融合经会阴前列腺穿刺活检对临床显著前列腺癌的检出率相似,尽管认知融合所取系统性穿刺针数更少。
- 软件融合平台的费用、额外时间需求与相似结局使认知融合经会阴前列腺穿刺活检具有更高价值。
研究设计与样本
- 回顾性多中心研究,时间范围为2020年6月至2022年7月,共纳入490例接受经会阴前列腺穿刺活检的患者,其中认知融合(PrecisionPoint)201例,软件融合289例。
- 融合方式的选择由术者偏好决定,收集的变量包括年龄、种族、前列腺特异性抗原(PSA)、前列腺体积、PI-RADS评分、病灶大小、取样针数、穿刺指征(PSA升高、既往阴性、主动监测)及麻醉类型。
- 采用多变量逻辑回归分析确定与经会阴穿刺检出临床显著前列腺癌相关的因素。
主要发现
- 患者年龄、PSA、靶病灶数目及PI-RADS评分在两组间相似(所有P > .05)。
- 软件融合组经会阴穿刺所取系统性穿刺针数中位数较认知融合组多4针(估计中位差值为4,95%CI 3-5)。
- 全部患者中临床显著前列腺癌(Grade Group ≥2)的检出率为44%。
- 调整分析中,认知融合与软件融合检出临床显著前列腺癌的比值比为1.46(95%CI 0.82-2.58),差异无统计学显著。
临床怎么用
- 作者认为,尽管认知融合所取系统性穿刺针数更少,其与软件融合对临床显著前列腺癌的检出率相似。
- 作者认为,软件融合平台的费用、额外时间需求与相似结局使认知融合经会阴前列腺穿刺活检具有更高价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare clinically significant prostate cancer detection with TP-TBx utilizing software vs cognitive fusion. It is established that MRI prior to prostate biopsy improves detection of clinically significant cancer (csPCa, Grade Group ≥2). MRI/US fusion targeted biopsy via a transperineal approach (TP-TBx) is increasing in utilization due to the clean percutaneous approach that greatly reduces postbiopsy infection. However, the comparative effectiveness of formal software fusion over cognitive fusion remains under studied. MATERIALS AND METHODS: We performed a retrospective multicenter study from June 2020 to July 2022 including age, race, prostate-specific antigen (PSA), prostate volume, PI-RADS, lesion size(s), number of cores sampled, indication (elevated PSA, prior negative, active surveillance) and anesthesia type. Surgeon preference determined use of cognitive (PrecisionPoint) vs software fusion techniques. Multivariable logistic regression determined factors associated with TP-TBx detection of csPCa. RESULTS: We identified 490 patients (201 cognitive, 289 software fusion) who underwent TP-TBx. Patient age, PSA, number of targets, and PI-RADS were similar (all P > .05). Software fusion TP-TBx had 4 [95% confidence interval (CI) 3-5] more (estimated median difference) systematic cores sampled. csPCa was detected in 44% of all patients. In adjusted analysis, cognitive vs software fusion was similar in detection of csPCa (odds ratio 1.46, 95% CI 0.82-2.58). CONCLUSION: Cognitive vs software fusion TP-TBx has similar csPCa detection, despite fewer systematic cores taken with cognitive fusion. The expense, additional time requirement, and similar outcomes of software fusion platforms confers higher value to cognitive TP-Bx.
引用
- Hung M, Ross AE, Li EV, et al. Prostate Cancer Detection Rate of Transperineal Prostate Biopsy: Cognitive vs Software Fusion, A Multicenter Analysis. Urology. 2024. PMID: 38387509. doi:10.1016/j.urology.2023.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。